ASH 2020: The Anti-Tumor Activity of IGM-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML

62nd American Society of Hematology (ASH) Annual Meeting and Exposition – December 5-8, 2020 – Session: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents

SITC 2020: Targeting IL-15 delivery to PD-L1 Expressing Tumors using an Anti-PDL1 x IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity

Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs – November 10-15, 2020

PEGS Europe 2020: Agonist IgM: Anti-Death Receptor 5 IgM Induces Tumor Cell Apoptosis in vitro and in vivo with a Favorable Safety Profile

PEGS Europe Virtual – November 12, 2020 – Program: Novel Targets and Emerging Therapeutic Areas

AACR 2020: A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release

American Association for Cancer Research (AACR) Annual Meeting II, Virtual – June 22-24, 2020

AACR 2020: Agonistic Death Receptor 5 (DR5) IgM antibody IGM-8444 induces tumor cell apoptosis in vitro and in vivo and has a favorable in vitro safety profile

American Association for Cancer Research (AACR) Annual Meeting II, Virtual – June 22–24, 2020 – Session: Antibody Technologies – Experimental and Molecular Therapeutics

AACR 2020: A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine release

American Association for Cancer Research (AACR) Annual Meeting II, Virtual – June 22–24, 2020 – Session: Therapeutics Antibodies 4 – Immunology